Pap smears, mammograms, colonoscopies, MRIs, thermography and cancer blood tests are being debated everywhere. Here’s what the evidence actually says.

If you spend enough time on social media, you will eventually encounter a frightening post telling women to avoid a Pap smear, mammogram, colonoscopy—or perhaps all three.

The arguments can sound convincing. Mammograms use radiation and compress the breast. Colonoscopies require sedation and carry a small risk of bleeding or perforation. Pap smears can be uncomfortable. Endoscopy is invasive. Meanwhile, newer technologies promise something far more appealing: an infrared camera, a blood draw, a stool sample, or a 60-minute MRI that scans almost your entire body.

Some of these technologies are genuinely exciting. Some are already excellent screening tools. Others may become transformative in the future.

But newer, less invasive or more technologically impressive does not automatically mean better at preventing cancer deaths.

And that’s where the conversation online can become dangerous.

At Agent Nateur, we’re interested in emerging science. But being open to new technology shouldn’t require rejecting established medicine. The better question isn’t natural versus conventional or old technology versus new technology.

It’s:

What does each test actually detect? What can it miss? And has it been shown to improve outcomes?

Here is where the science stands in 2026.

CERVICAL CANCER

Is a Pap smear still the best screening test?

This is one area where the answer has genuinely changed.

A Pap smear examines cervical cells under a microscope to identify abnormal or precancerous cellular changes.

But virtually all cervical cancers are driven by persistent infection with certain high-risk strains of human papillomavirus (HPV).

Instead of waiting for HPV to produce visible cellular abnormalities, an HPV test looks for the high-risk virus itself.

And current U.S. recommendations have moved accordingly.

Updated federal women’s preventive health guidelines designate high-risk HPV testing as the preferred screening modality for average-risk women ages 30–65, while Pap cytology remains an option. Pap screening remains recommended for average-risk women ages 21–29. 

There’s another major development: self-collection.

FDA-authorized HPV tests now allow certain women to collect their own vaginal sample rather than having a clinician collect cervical cells during a pelvic examination. Studies have found high agreement between appropriately performed self-collected and clinician-collected HPV samples. 

That means a woman who has been avoiding cervical screening because she doesn’t want a traditional Pap/pelvic examination may now have another evidence-based option.

Is HPV testing “better” than a Pap?

For women in the appropriate age and risk group, primary high-risk HPV testing is no longer an alternative fringe test—it is a preferred screening strategy.

But an HPV test isn’t a cancer diagnosis.

A positive HPV result may require additional testing. Depending on the HPV genotype and previous history, that can eventually mean cervical cytology, colposcopy and potentially a biopsy.

And this distinction matters:

Screening identifies risk or abnormalities. A biopsy diagnoses cancer.

A doctor can also visually examine the cervix, but a normal-looking cervix cannot reliably exclude microscopic precancer.

There is currently no routine blood test, ultrasound, CT or MRI that replaces appropriate cervical cancer screening.

THE VERDICT

Pap: Evidence-based and still useful.

Primary high-risk HPV: Evidence-based and now preferred for many women 30–65.

Self-collected HPV: A major new option for appropriately selected women.

MRI/ultrasound/blood testing: Not substitutes for cervical screening.

Biopsy: The definitive diagnostic test when cancer is suspected.

This is actually a perfect example of medicine evolving: there is now a legitimate alternative to the traditional Pap-centered approach.

BREAST CANCER

This is where some of the most concerning misinformation exists.

Mammography

Mammography uses low-dose X-rays to identify abnormalities within breast tissue—sometimes before a mass can be felt.

It isn’t perfect.

Mammography can produce false positives. Dense breast tissue can make interpretation more difficult. Screening can detect cancers that might never have become clinically significant, known as overdiagnosis. There is radiation exposure, although the dose is low. And yes, compression can be uncomfortable.

Those are legitimate limitations and deserve discussion.

But they don’t establish that an alternative test is equally effective.

The FDA continues to describe mammography as the most effective primary breast-cancer screening method for detecting cancer at an early, more treatable stage. 

What about thermography?

Thermography sounds extraordinarily attractive.

There is:

• no radiation
• no breast compression
• no injection
• no physical contact

An infrared camera measures patterns of heat and blood flow near the surface of the breast.

The theory is that tumors may produce changes in metabolism and vascular activity that alter thermal patterns.

But here’s the critical distinction:

Thermography isn’t actually imaging the internal anatomy of the breast the way mammography or MRI does.

And despite claims circulating online, there is currently insufficient evidence that thermography can safely replace mammography.

The FDA explicitly states that thermography has not been demonstrated to be effective as a standalone breast-cancer screening test and warns that relying on it instead of mammography can result in cancers being missed. Thermography devices have been cleared only as adjunctive tools—not replacements for mammography. 

THE VERDICT

Thermography may provide interesting physiological information.

But:

A normal thermogram does not mean you have been adequately screened for breast cancer.

That distinction is enormously important.

WHAT ABOUT QT BREAST SCANS?

One technology getting a lot of attention right now is QT Imaging, sometimes referred to as a QT breast scan or Breast Acoustic CT™.

And this one deserves its own discussion because QT is not thermography.

QT Imaging uses ultrasound technology—including reflection and transmission imaging—to create detailed three-dimensional images of breast tissue. The breast is scanned without the compression used during a mammogram, without an injection of contrast, and without ionizing radiation. (FDA Access Data⁠)

Those are meaningful advantages.

The technology is also FDA-cleared. The QT Scanner received previous FDA clearances, and in March 2026 the FDA cleared an updated configuration designed to improve visualization of breast tissue closer to the chest wall. (FDA Access Data⁠)

So when people lump QT together with thermography as simply another “alternative mammogram,” they’re missing an important distinction.

QT IMAGING VS. THERMOGRAPHY

Thermography measures patterns of heat at or near the surface of the breast.

QT actually images the internal breast using ultrasound.

They are fundamentally different technologies.

The FDA has specifically warned that thermography has not been demonstrated to be an effective standalone breast-cancer screening test and should not replace mammography. (U.S. Food and Drug Administration⁠)

QT is much more interesting from an imaging standpoint. It creates anatomical images of the breast and can quantitatively assess fibroglandular tissue and breast density. (QT Imaging⁠)

But here is where social media tends to leave out an extremely important sentence:

FDA-CLEARED DOES NOT AUTOMATICALLY MEAN “CLEARED TO REPLACE A MAMMOGRAM.”

QT Imaging itself states that its current FDA clearance does not establish the technology as a replacement for mammography for breast-cancer screening. (QT Imaging⁠)

That distinction matters.

Mammography has decades of screening data behind it and remains a recommended primary screening modality. One of its particular strengths is its ability to identify suspicious calcifications and microcalcifications, which can sometimes be associated with very early breast cancers such as ductal carcinoma in situ.

QT and other ultrasound-based technologies visualize breast tissue differently.

That doesn’t make QT inferior technology. In fact, the absence of radiation and compression and its ability to create detailed 3D breast images make it one of the breast-imaging technologies we think is genuinely worth watching.

But promising technology and proven replacement are not the same thing.

WHAT ABOUT DENSE BREASTS?

This is where the conversation becomes especially interesting.

Dense breast tissue can make cancers more difficult to see on mammography because dense tissue and some tumors can both appear white on a mammogram.

QT does not rely on X-rays and can provide three-dimensional information about breast tissue. Its FDA-cleared technology can also quantitatively measure fibroglandular tissue volume and the proportion of fibroglandular tissue within the breast. (QT Imaging⁠)

That could make technologies like QT particularly interesting as supplemental imaging.

But current American College of Radiology breast-screening guidance still considers mammography or digital breast tomosynthesis appropriate primary screening examinations. Depending on a woman’s risk and breast density, ultrasound or contrast-enhanced breast MRI may be considered supplemental examinations. (ACR Search⁠)

QT has not yet displaced those recommendations.

WHAT ABOUT BREAST MRI?

Now we get into a genuinely powerful technology.

MRI doesn’t use ionizing radiation. Instead, it uses a strong magnetic field and radiofrequency energy to produce highly detailed images.

Breast MRI can detect cancers that mammography misses.

So why don’t we simply replace mammograms with MRI?

Because MRI has a different set of limitations.

It is extremely sensitive—which sounds universally positive until you realize that high sensitivity can also identify many abnormalities that aren’t cancer.

That can mean additional imaging, anxiety and unnecessary biopsies.

More importantly, MRI and mammography don’t detect exactly the same things. Certain cancers or calcifications visible on mammography may not be identified by MRI.

For women at sufficiently high risk, the American Cancer Society recommends MRI plus mammography, not MRI instead of mammography. 

That is an important theme throughout cancer screening:

The most advanced technology isn’t necessarily a replacement. Sometimes it is an additional layer.

WHAT ABOUT PRENUVO AND WHOLE-BODY MRI?

Whole-body MRI is fascinating technology.

Companies such as Prenuvo offer extensive MRI examinations designed to identify potential tumors and other abnormalities throughout much of the body—without ionizing radiation.

For someone interested in proactive health monitoring, the appeal is obvious.

But a whole-body MRI and established cancer screening aren’t interchangeable.

MRI may identify certain tumors very well while being relatively poor at identifying other early cancers or precancerous lesions.

For example:

A whole-body MRI doesn’t scrape cells from your cervix.

It doesn’t detect microscopic blood or abnormal DNA shed by a colon polyp.

It doesn’t examine the lining of the esophagus and take a biopsy.

And it isn’t identical to a dedicated breast MRI protocol.

The American College of Radiology currently says there isn’t sufficient evidence to recommend total-body MRI screening for asymptomatic people without relevant risk factors or family history. It also warns about incidental findings that can trigger additional testing without necessarily improving health outcomes. 

So whole-body MRI can potentially complement conventional screening.

It should not currently be viewed as a universal replacement for it.

WHAT ABOUT A BLOOD TEST THAT LOOKS FOR CANCER?

This may eventually become one of the most consequential developments in cancer screening.

Researchers are developing multi-cancer detection blood tests that search for signals such as circulating tumor DNA, methylation patterns and other cancer-associated biomarkers.

The concept is extraordinary:

One tube of blood.

Multiple cancers.

Potentially years earlier.

But there’s a tremendous difference between showing that a blood test can detect a cancer signal and proving that screening healthy people with that test ultimately saves lives.

The National Cancer Institute notes that multi-cancer detection tests have not yet demonstrated a reduction in cancer mortality in randomized trials, and none has FDA authorization as a broad multi-cancer screening assay. 

There are also difficult questions:

What happens when a blood test says “cancer signal detected” but imaging can’t locate a tumor?

How many cancers are missed?

How many positive signals turn out not to be cancer?

Does finding every microscopic cancer earlier actually improve survival?

These aren’t arguments against the technology.

They’re the questions that have to be answered before we tell millions of healthy people to replace proven screening with it.

COLORECTAL CANCER

Here’s another area where people deserve more nuance.

Colonoscopy is not the only legitimate screening option.

A colonoscopy uses a flexible camera to examine the entire colon.

Its enormous advantage is that it can do something many other screening tests cannot:

It can find a precancerous polyp and remove it during the same procedure.

In other words, colonoscopy can potentially prevent cancer rather than simply discover it.

But colonoscopy has disadvantages.

It requires bowel preparation. Usually sedation. Someone generally has to drive you home. There are small but genuine risks including bleeding and bowel perforation, and those risks increase with age. 

For an average-risk person who doesn’t want a colonoscopy, however, there are legitimate alternatives.

FIT

The fecal immunochemical test looks for microscopic blood in stool.

It can be performed at home and doesn’t require anesthesia or bowel preparation.

When performed at recommended intervals, FIT is an accepted colorectal screening strategy.

The downside?

It needs to be repeated regularly, and a positive FIT requires a colonoscopy.

Stool DNA + FIT

Stool DNA testing looks for abnormal DNA shed from cancerous or precancerous tissue while also testing for blood.

It has greater one-time sensitivity than FIT alone, but lower specificity—meaning more false positives and therefore more follow-up colonoscopies. 

Again:

A positive stool test isn’t the end of the screening process. It’s the beginning of a diagnostic workup.

CT colonography

Sometimes called a “virtual colonoscopy,” CT colonography uses imaging to reconstruct the colon.

It avoids sedation and inserting a colonoscope through the entire colon.

But it still generally requires bowel preparation, involves radiation, and if a significant polyp is found:

you still need a colonoscopy to remove it.

The USPSTF recognizes FIT, stool DNA-FIT, CT colonography, flexible sigmoidoscopy and colonoscopy as evidence-based colorectal screening strategies for appropriate average-risk adults. 

So telling everyone that colonoscopy is the only valid colorectal screening test would also be inaccurate.

WHAT ABOUT A BLOOD TEST FOR COLON CANCER?

This has recently become much more interesting.

In 2024, the FDA approved Shield, a blood-based screening test for colorectal cancer in average-risk adults 45 and older. It detects cancer-associated alterations in circulating DNA. 

That’s meaningful progress.

But blood-based colorectal screening should not be confused with colonoscopy’s ability to directly identify and remove precancerous polyps.

A blood test may make screening accessible to people who otherwise wouldn’t screen at all—which could be enormously valuable.

But it doesn’t turn a blood draw into a colonoscopy.

ESOPHAGEAL CANCER, BARRETT’S ESOPHAGUS AND ENDOSCOPY

Upper endoscopy is another procedure sometimes lumped into the “unnecessary invasive testing” narrative.

An endoscopy passes a thin flexible camera through the mouth to examine the esophagus, stomach and beginning of the small intestine.

For certain conditions, the key advantage isn’t merely seeing the tissue.

It’s biopsying it.

That is especially important with Barrett’s esophagus.

Barrett’s involves a microscopic change in the cells lining the esophagus. A camera can identify suspicious areas, but tissue examination is fundamental to confirming Barrett’s and determining whether dysplasia or cancerous changes are present.

The American College of Gastroenterology describes endoscopy as the test of choice for Barrett’s and emphasizes the importance of biopsy tissue for diagnosis. 

Can MRI replace an endoscopy?

No.

MRI can provide extraordinary anatomical information, but it cannot currently examine the esophageal lining at microscopic resolution and then remove tissue for pathology.

Can a blood test replace it?

Not currently.

Researchers are investigating biomarkers and minimally invasive approaches, including swallowable sponge/capsule devices that collect esophageal cells. The American College of Gastroenterology describes these as promising, but they have not simply replaced endoscopy and biopsy. 

For someone with known Barrett’s or other significant risk factors, surveillance is a different question from general-population screening and should be individualized with a gastroenterologist.

THE PROBLEM WITH “THIS TEST IS DANGEROUS” CONTENT

There is nothing wrong with questioning medicine.

In fact, medicine advances precisely because people question existing practices.

Screening has real downsides.

False positives exist.

False negatives exist.

Overdiagnosis exists.

Radiation matters.

Complications from invasive procedures matter.

Unnecessary biopsies matter.

Individual risk matters.

And informed consent matters.

But questioning a screening test and telling millions of people that an unproven alternative provides equivalent protection are two entirely different things.

That’s where wellness misinformation becomes genuinely dangerous.

Someone who believes thermography has “cleared” her breasts may skip mammography despite thermography’s inability to reliably exclude early breast cancer.

Someone may purchase a whole-body MRI and assume that means they no longer need cervical or colorectal screening.

Someone may get an expensive multi-cancer blood test, receive a reassuring result and believe they have been cleared of cancer.

That isn’t what these technologies currently establish.

THE OTHER SIDE OF THE CONVERSATION MATTERS TOO

Fear shouldn’t be used in the opposite direction either.

Not every person requires every available screening procedure.

More testing isn’t automatically better.

The correct screening strategy depends on age, genetics, family history, previous findings, symptoms, breast density, HPV history, smoking history and numerous other factors.

And alternatives do exist.

That’s the nuance that gets lost online.

For cervical cancer, primary HPV screening may actually replace Pap cytology for many women.

For colorectal cancer, FIT and stool DNA-based strategies are legitimate evidence-based alternatives to screening colonoscopy for many average-risk people, provided appropriate intervals and follow-up are observed.

For women at high breast-cancer risk, MRI can add substantial detection capability—but is generally used alongside mammography rather than replacing it.

And emerging blood tests may eventually reshape cancer screening altogether.

Science isn’t standing still.

OUR TAKEAWAY

We don’t believe women should be frightened into medical procedures.

We also don’t believe they should be frightened out of them.

Ask questions.

Ask about absolute risk.

Ask about radiation.

Ask about false positives.

Ask about false negatives.

Ask whether you qualify for HPV self-collection.

Ask whether breast density changes your screening strategy.

Ask whether FIT is appropriate instead of screening colonoscopy.

Ask whether your family history changes everything.

Ask what an MRI can detect—and what it cannot.

And whenever someone tells you that a new test is “better,” ask one more question:

Better at what?

More sensitive?

Less invasive?

More comfortable?

Better at detecting advanced cancer?

Better at detecting precancer?

Or actually demonstrated to reduce the likelihood of dying from that cancer?

Those are very different claims.

We are living through an extraordinary period in preventive medicine. HPV molecular testing, advanced MRI, circulating tumor DNA, artificial intelligence and increasingly sophisticated molecular diagnostics may dramatically change how we screen for cancer.

We should embrace that innovation.

But until a newer technology has demonstrated that it can safely replace an established test, the most scientifically responsible approach isn’t old medicine versus new medicine.

It’s using the right technology for the thing it has actually been proven to do.

This article is educational and is not individualized medical advice. Screening recommendations differ for people with symptoms, previous abnormal results, known precancerous conditions, genetic syndromes, strong family histories or other elevated risks. Those situations should be discussed individually with a qualified healthcare professional.